The Role of Neurotransmitters in the Pathophysiology of Schizophrenia: A Meta-Analysis
International Journal of Pharmaceutical Quality Assurance · 30.06.2026 · 17 (06)
DOI: 10.25258/ijpqa.17.6.32 ↗Kurz gefasst
Metaanalyse in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.06.2026. Verfasst von Basalingappa Basalingappa.
Abstract (Originalsprache)
Schizophrenia is a chronic and complex psychiatric condition marked by positive symptoms (such as hallucinations and delusions), negative symptoms (such as reduced emotional expression and social withdrawal), and a range of cognitive impairments. Dysregulation of various neurotransmitters has been extensively discussed as a core feature of its pathogenesis, with dopamine traditionally holding a central position. However, accumulating data suggest that other transmitter systems—including glutamate, gamma-aminobutyric acid (GABA), and serotonin—also significantly influence the emergence and maintenance of schizophrenic symptoms. This meta-analysis aims to integrate findings on key neurotransmitters (dopamine, glutamate, GABA, and serotonin) in schizophrenia, particularly focusing on differences between those with schizophrenia and unaffected individuals. We performed systematic searches in PubMed, Scopus, and Web of Science for literature published from January 2015 to May 2023. Eligible studies included those with a formal diagnosis of schizophrenia, robust measures of neurotransmitter or receptor function, and sufficient numerical data to calculate standardized effect sizes. A total of 62 studies (comprising 4,857 people with schizophrenia and 3,211 comparison subjects) met the criteria. Results revealed that dopaminergic markers (notably, D2 receptor availability) exhibited a strong pooled effect size (~0.91), reinforcing long-standing dopaminergic models. Glutamatergic findings, especially reductions in NMDA receptor activity, showed a moderate-to-large effect (~0.67). GABAergic anomalies (e.g., decreased inhibitory markers like GAD67) displayed a moderate effect (~0.59). Meanwhile, serotonergic alterations (often elevated 5-HT2A receptor activity) yielded a modest but statistically significant effect (~0.48). Substantial variability was noted across study approaches and participant characteristics. In conclusion, while dopamine remains pivotal, significant disruptions in glutamate, GABA, and serotonin also appear to shape the symptom profile of schizophrenia. Future research, employing multimodal and longitudinal designs, is essential to unravel how these neurotransmitter interactions may inform more nuanced treatment strategies.
Zitieren
APA
Basalingappa, B. (2026). The Role of Neurotransmitters in the Pathophysiology of Schizophrenia: A Meta-Analysis. International Journal of Pharmaceutical Quality Assurance, 17(06). https://doi.org/10.25258/ijpqa.17.6.32
Vancouver
Basalingappa B. The Role of Neurotransmitters in the Pathophysiology of Schizophrenia: A Meta-Analysis. International Journal of Pharmaceutical Quality Assurance. 2026;17(06). doi:10.25258/ijpqa.17.6.32
BibTeX
@article{Basalingappa2026,
author = {Basalingappa, Basalingappa},
title = {The Role of Neurotransmitters in the Pathophysiology of Schizophrenia: A Meta-Analysis},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {06},
doi = {10.25258/ijpqa.17.6.32}
}
EUVIMED